^
    over1year
    Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial. (PubMed, Front Oncol)
    The potential benefit of combined inhibition of Ang-2 and VEGF-A in previously untreated patients with mCRC was evaluated in the phase II McCAVE study (NCT02141295), assessing vanucizumab versus bevacizumab (VEGF-A inhibitor), both in combination with mFOLFOX-6 (modified folinic acid [leucovorin], fluorouracil and oxaliplatin) chemotherapy. These data suggest that Ang-2 may be both a prognostic biomarker in mCRC and a predictive biomarker for vanucizumab in KRAS wild-type mCRC. Thus, this evidence can potentially support the establishment of more tailored treatment approaches for patients with mCRC.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS wild-type • RAS wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • vanucizumab (RG7221)
    6years
    Combination of subcutaneous selicrelumab (CD40 agonist) and vanucizumab (anti-Ang2/VEGF) in patients with solid tumors demonstrates early clinical activity and a favorable safety profile (SITC 2018)
    Trial Registrationl This study is registered on Clinicaltrials.gov: NCT02665416 ; Background Selicrelumab is a fully human agonistic IgG2 monoclonal antibody to CD40, a member of the TNFreceptor superfamily expressed on antigenpresenting cells (APC), endothelial cells and some tumors. The combination demonstrated a favorable safety profile with no evidence for systemic autoimmune toxicity. The results triggered an expansion of the study in selected tumor indications with 16mg SC selicrelumab in combination with bevacizumab (anti- VEGF).
    Clinical • IO biomarker
    |
    ANGPT2 (Angiopoietin 2)
    |
    Avastin (bevacizumab) • selicrelumab (RG7876) • vanucizumab (RG7221)
    over6years
    Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors (clinicaltrials.gov)
    P1; N=170; Recruiting; Sponsor: Hoffmann-La Roche; Trial completion date: Nov 2019 --> Jun 2020; Trial primary completion date: Nov 2019 --> Jun 2020
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • selicrelumab (RG7876) • vanucizumab (RG7221)